// App-Quantinova.ai

241 : First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study.

Researchers

Presenter

  • Jean-Philippe Metges

Principal Investigators

  • Jong-Mu Sun

  • Manish A. Shah

  • Peter C. Enzinger

  • Antoine Adenis

  • Toshihiko Doi

  • Takashi Kojima

  • Zhigang Li

  • Sung-Bae Kim

  • Byoung Chul Cho

  • Wasat Mansoor

  • Shau-Hsuan Li

  • Patrapim Sunpaweravong

  • MARIA ALSINA

  • Gary L Buchschacher

  • Jimin Wu

  • Sukrut Shah

  • Pooja Bhagia

  • Lin Shen

Medical Centers

  • CHU Brest–Institut de Cancerologie et d’Hematologie ARPEGO Network, Brest, France

  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • Weill Cornell Medical College, New York, NY

  • Center for Esophageal and Gastric Cancer, Dana-Farber Cancer Institute, Boston, MA

  • IRMB Inserm U1183, Université de Montpellier, Montpellier, France

  • National Cancer Center, EPOC, Chiba, Japan

  • Depertment of Surgical Oncology, National Cancer Center Hospital East, Chiba, Japan

  • Shanghai Chest Hospital Esophageal Disease Center, Shanghai, China

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • Gangnam Severance Hospital, Yonsei University Health System, Seoul, Korea

  • The Christie Hospital, Manchester, United Kingdom

  • Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan

  • Prince of Songkla University, Hat Yai, Thailand.

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Kaiser Permanente Southern California, Los Angeles Medical Center, Los Angeles, CA

  • Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Kenilworth NJ United States

  • Department of Thoracic Medical Oncology, Peking University Cancer Hospital & Institute, Beijing, China

Locations

  • France

  • Japan

  • Republic of South Korea

  • United States

  • China

  • United Kingdom

  • Taiwan

  • Thailand

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Esophageal Cancer

  • Esophageal squamous carcinoma cell

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Cross Over

Phase

  • III

Study Id's

  • NCT03189719

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved